Fulgent Genetics, Inc. (FLGT) Misses Q2 EPS by 26c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/17/2026
- Generac strikes $8B supply deal with Amazon for data center power
- Wall St ends lower after Fed hikes interest rates, sees more tightening ahead
- Paradium AI (PAAI) Halted, News Pending
- Shipping stocks on fire — but cracks are forming in the rate rally
- JPMorgan Fed scenario analysis: 5 paths for the S&P 500 today
Fulgent Genetics, Inc. (FLGT) Enters Collaboration with Helio Health for Early Cancer Detection Tests
August 9, 2021 4:04 PM EDTFulgent Genetics, Inc. (NASDAQ: FLGT) and Helio Health announced the companies have entered into a strategic partnership to commercialize Helios blood-based early cancer detection tests. In conjunction with the commercial strategic partnership whereby the company has secured exclusive commercial rights for laboratory develop tests (LDTs) in the U.S. and Canada, Fulgent has made a strategic investment in Helio.
Under this partnership, the companies will initially commercialize and co-brand HelioLiver, a cell-free DNA (cfDNA) methylation blood test that incorporates protein markers and demographics for the detection of hepatocellular carcinoma (HCC) or liver cancer.... More
Fulgent Genetics, Inc. (FLGT) to Acquire CSI Laboratories
August 9, 2021 4:03 PM EDTFulgent Genetics, Inc. (NASDAQ: FLGT) announced that it has acquired CSI Laboratories to expand its presence in somatic molecular diagnostics and cancer testing.
CSI was founded in 1997 to provide a client- and patient-focused model of cancer diagnostic testing for pathologists, community hospitals, and their patients. CSI offers more than 400 unique tests with a focus on oncology and capabilities across flow cytometry, cytogenetic analysis, fluorescence in-situ hybridization (FISH), immunohistochemistry, and molecular genetics. CSIs philosophy of providing expert diagnostic testing with speed, precision, and care, is highly complementary with Fulgents core value... More
